{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:00:51Z","timestamp":1771660851094,"version":"3.50.1"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.thromres.2004.09.010","type":"journal-article","created":{"date-parts":[[2004,12,22]],"date-time":"2004-12-22T01:34:55Z","timestamp":1103679295000},"page":"287-292","source":"Crossref","is-referenced-by-count":20,"title":["Thrombin activatable fibrinolysis inhibitor in Beh\u00e7et's disease"],"prefix":"10.1016","volume":"115","author":[{"given":"Ayhan","family":"Donmez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenan","family":"Aksu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Handan Ak","family":"Celik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokhan","family":"Keser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seckin","family":"Cagirgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serdar Bedii","family":"Omay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vedat","family":"Inal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hikmet Hakan","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murat","family":"Tombuloglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eker","family":"Doganavsargil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2004.09.010_bib1","first-page":"1152","article-title":"\u00dcber rezidiverende aphth\u00f6se durch ein virus verursachte Geschw\u00fcre am Mund, am Auge, und an den Genitalien","volume":"105","author":"Beh\u00e7et","year":"1937","journal-title":"Dermatol. Wochenschr."},{"key":"10.1016\/j.thromres.2004.09.010_bib2","first-page":"402","article-title":"Vascular involvement in Beh\u00e7et's disease","volume":"19","author":"Koc","year":"1992","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2004.09.010_bib3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1093\/rheumatology\/40.6.652","article-title":"Thrombosis in Beh\u00e7et's disease: a retrospective survey from a single UK centre","volume":"40","author":"Ames","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2004.09.010_bib4","first-page":"1","article-title":"Beh\u00e7et's syndrome","volume":"vol. 2","author":"Yazici","year":"1998"},{"key":"10.1016\/j.thromres.2004.09.010_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1046\/j.1365-2796.1996.396853000.x","article-title":"Impaired haemostatic kinetics and endothelial function in Beh\u00e7et's disease","volume":"240","author":"Haznedaroglu","year":"1996","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.thromres.2004.09.010_bib6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0735-1097(00)01137-2","article-title":"Vascular endothelial function and oxidative stress mechanisms in patients with Beh\u00e7et's syndrome","volume":"37","author":"Chambers","year":"2001","journal-title":"J. Am. Coll. Cardiol."},{"issue":"Suppl 24","key":"10.1016\/j.thromres.2004.09.010_bib7","first-page":"25","article-title":"Interactions of nitric oxide and superoxide dismutase in Beh\u00e7et's disease","volume":"19","author":"Kiraz","year":"2001","journal-title":"Clin. Exp. Rheumatol."},{"issue":"6","key":"10.1016\/j.thromres.2004.09.010_bib8","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/rheumatology\/40.6.687","article-title":"Hyperhomocysteinaemia in Beh\u00e7et's disease","volume":"40","author":"Aksu","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.thromres.2004.09.010_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0049-3848(02)00006-3","article-title":"Pathological haemostasis and \u2018prothrombotic state\u2019 in Beh\u00e7et's disease","volume":"105","author":"Kiraz","year":"2002","journal-title":"Thromb. Res."},{"key":"10.1016\/j.thromres.2004.09.010_bib10","first-page":"496","article-title":"Factor V Leiden mutation in patients with Beh\u00e7et's disease","volume":"25","author":"Oner","year":"1998","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2004.09.010_bib11","first-page":"2849","article-title":"Effects of factor V gene G1691A, methylenetetrahydrofolate reductase gene C677T, and prothrombin gene G20210A mutations on deep venous thrombosis in Beh\u00e7et's disease","volume":"27","author":"Toydemir","year":"2000","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.thromres.2004.09.010_bib12","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archopht.1985.01050070061030","article-title":"Plasminogen activator activity levels in patients with Beh\u00e7et's syndrome","volume":"103","author":"Mishima","year":"1985","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.thromres.2004.09.010_bib13","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000040847","article-title":"Haemostasis, thrombosis, and endothelium in Beh\u00e7et's disease","volume":"99","author":"Haznedaroglu","year":"1998","journal-title":"Acta Haematol."},{"key":"10.1016\/j.thromres.2004.09.010_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00001721-200302000-00001","article-title":"Factor V Leiden mutation and PAI-1 gene 4G\/5G genotype in thrombotic patients with Beh\u00e7et's disease","volume":"14","author":"Gurgey","year":"2003","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.thromres.2004.09.010_bib15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1055\/s-0038-1646409","article-title":"Coagulation and fibrinolytic activity in Beh\u00e7et's disease","volume":"66","author":"Hampton","year":"1991","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.thromres.2004.09.010_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00296-001-0143-1","article-title":"Unchanged global fibrinolytic capacity despite increased factor VIIa activity in Beh\u00e7et's disease: evidence of a prethrombotic state","volume":"21","author":"Ozatli","year":"2002","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.thromres.2004.09.010_bib17","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1046\/j.1538-7836.2003.00329.x","article-title":"Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U)","volume":"1","author":"Bouma","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2004.09.010_bib18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1568006013337999","article-title":"Thrombin activatable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders","volume":"1","author":"Boffa","year":"2001","journal-title":"Curr. Drug Targets Cardiovasc. Haematol. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2004.09.010_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1053\/j.seminhematol.2003.11.004","article-title":"New insights into factors affecting clot stability: a role for thrombin activatable fibrinolysis inhibitor (TAFI; plasma procarboxypeptidase B, plasma procarboxypeptidase U, procarboxypeptidase R)","volume":"41","author":"Bouma","year":"2004","journal-title":"Semin. Hematol."},{"issue":"3","key":"10.1016\/j.thromres.2004.09.010_bib20","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1046\/j.1365-2141.2000.01890.x","article-title":"Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia","volume":"108","author":"Meijers","year":"2000","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.thromres.2004.09.010_bib21","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/jhep.2003.50277","article-title":"Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis","volume":"38","author":"Colucci","year":"2003","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.thromres.2004.09.010_bib22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1055\/s-0037-1615651","article-title":"Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease","volume":"85","author":"Van Thiel","year":"2001","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.thromres.2004.09.010_bib23","doi-asserted-by":"crossref","first-page":"9250","DOI":"10.1074\/jbc.M209588200","article-title":"Acute phase mediators modulate thrombin-activatable fibrinolysis inhibitor (TAFI) gene expression in HepG2 cells","volume":"278","author":"Boffa","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.thromres.2004.09.010_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.4049\/jimmunol.165.2.1053","article-title":"Pro-Carboxypeptidase R is an acute phase protein in the mouse, whereas carboxypeptidase n is not","volume":"165","author":"Sato","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.thromres.2004.09.010_bib25","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2004.09.010_bib26","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0002-9343(01)01048-8","article-title":"Vascular involvement in Beh\u00e7et's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin","volume":"112","author":"Espinosa","year":"2002","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.thromres.2004.09.010_bib27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1055\/s-0037-1613387","article-title":"Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. The PRIME Study (Prospective Epidemiological Study of MI)","volume":"89","author":"Morange","year":"2003","journal-title":"Thromb. Haemost."},{"issue":"5","key":"10.1016\/j.thromres.2004.09.010_bib28","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1161\/01.ATV.0000015445.22243.F4","article-title":"Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe","volume":"22","author":"Juhan-Vague","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.thromres.2004.09.010_bib29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1055\/s-0037-1613604","article-title":"Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris","volume":"90","author":"Brouwers","year":"2003","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2004.09.010_bib30","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1161\/01.STR.0000063139.06585.45","article-title":"Thrombin-activatable fibrinolysis inhibitor levels in the acute phase of ischemic stroke","volume":"34","author":"Montaner","year":"2003","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2004.09.010_bib31","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1182\/blood.V95.9.2855.009k02_2855_2859","article-title":"Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis","volume":"95","author":"Van Tilburg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2004.09.010_bib32","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1161\/01.STR.0000088642.07691.15","article-title":"Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels","volume":"34","author":"Santamar\u00eda","year":"2003","journal-title":"Stroke"},{"issue":"6","key":"10.1016\/j.thromres.2004.09.010_bib33","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1046\/j.1365-2141.2003.04549.x","article-title":"Thrombin-activatable fibrinolysis inhibitor in young patients with myocardial infarction and its relationship with the fibrinolytic function and the protein C system","volume":"122","author":"Zorio","year":"2003","journal-title":"Br. J. Haematol."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384804005018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384804005018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T21:40:45Z","timestamp":1586036445000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384804005018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0049384804005018"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2004.09.010","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}